AZP IL4R
Alternative Names: AZP-IL-4R-AD1; AZP-IL-4R-BA1; AZP-IL4RLatest Information Update: 08 Nov 2023
At a glance
- Originator Azcuris
- Class Anti-inflammatories; Antiasthmatics; Skin disorder therapies; Small molecules
- Mechanism of Action Interleukin 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Asthma; Atopic dermatitis
Most Recent Events
- 08 Nov 2023 AZP IL4R is available for licensing as of 08 Nov 2023. http://www.azcuris.com/ (Azcuris pipeline, November 2023)
- 08 Nov 2023 Early research in Asthma in South Korea (PO) prior to November 2023 (Azcuris pipeline, November 2023)
- 08 Nov 2023 Early research in Atopic dermatitis in South Korea (PO) prior to November 2023 (Azcuris pipeline, November 2023)